![Paula Cloghessy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Paula Cloghessy
Nessuna posizione attualmente
Patrimonio netto: 33 075 $ in data 30/06/2024
Storia della carriera di Paula Cloghessy
Precedenti posizioni note di Paula Cloghessy
Società | Posizione | Inizio | Fine |
---|---|---|---|
SERES THERAPEUTICS, INC. | Ufficiale delle Risorse Umane | 07/02/2022 | 31/12/2023 |
TRANSLATE BIO, INC. | Ufficiale delle Risorse Umane | 01/01/2017 | 14/09/2021 |
Joule Unlimited Technologies, Inc.
![]() Joule Unlimited Technologies, Inc. Industrial SpecialtiesProcess Industries Joule Unlimited Technologies, Inc. produces renewable fuels and chemicals. It offers a technology platform for liquid fuel from the Sun. The company was founded by Noubar B. Afeyan in 2007 and is headquartered in Bedford, MA. | Ufficiale delle Risorse Umane | 01/01/2010 | 01/04/2016 |
Formazione di Paula Cloghessy
University of Massachusetts | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 5 |
Posizioni
Human Resources Officer | 3 |
Undergraduate Degree | 1 |
Settori
Health Technology | 3 |
Process Industries | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
SERES THERAPEUTICS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Joule Unlimited Technologies, Inc.
![]() Joule Unlimited Technologies, Inc. Industrial SpecialtiesProcess Industries Joule Unlimited Technologies, Inc. produces renewable fuels and chemicals. It offers a technology platform for liquid fuel from the Sun. The company was founded by Noubar B. Afeyan in 2007 and is headquartered in Bedford, MA. | Process Industries |
Translate Bio, Inc.
![]() Translate Bio, Inc. BiotechnologyHealth Technology Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA. | Health Technology |
- Borsa valori
- Insiders
- Paula Cloghessy
- Esperienza